This article was previously published with some errors. There was a discrepancy between the abstract and the full text regarding the number of patients on continuous hydroxychloroquine therapy over 5 ...

Introduction Anifrolumab (Saphnelo) is approved for adult patients with moderate-severe systemic lupus erythematosus (SLE). Considering its commercialisation in Spain in 2023, observational studies ...

Hemophagocytic lymphohistiocytosis (HLH) is a well-recognised complication of systemic lupus erythematosus (SLE). In one small case series, HLH was noted in approximately 5% of patients with lupus. 1 ...

The molecular dissection of the immune system and the identification of druggable targets have played major roles in the biotechnology revolution. In particular, the evolution of therapeutic ...

Despite advancements in lupus management over the past two decades, infection remains a significant cause of morbidity and mortality among patients with systemic lupus erythematosus (SLE). 1 2 Various ...

PRIME TIME SESSION: (HYBRID) PART I: BABY YOU CAN DRIVE MY CAR-T CELLS ... AND OTHER NOVEL THERAPIES ...

Background/ Purpose We recently showed that in SLE, IL-4 suppressed the development of interferon-beta (IFNβ) and TLR7-stimulated T-bet + double negative 2 (DN2) B cells. Here we investigate the ...

Objective Patients with lupus erythematosus (LE) are at heightened risk for clinical events, chiefly heart attacks and strokes, from atherosclerotic cardiovascular disease (ASCVD). We recently ...

Conclusions We report substantial differences in lupus nephritis mortality rates by sex, age, geographic region, urbanization level, and race/ethnicity. This study suggests strong, independent and ...

Objective BAFF and APRIL signal through TACI, BCMA, and/or BAFF-R, and play important roles in the activation, differentiation, and/or survival of B cells, particularly antibody-secreting cells, as ...

Objective We investigated DORIS (Definition of Remission in SLE) attainment in patients with SLE in the placebo-controlled phase 3 TULIP long-term extension (LTE) trial of anifrolumab. DORIS ...

LBP1 Interim results of an open-label, multicentre, Phase 1/2 study to assess YTB323 (rapcabtagene autoleucel), a CAR T-cell therapy, for severe refractory systemic lupus erythematosus ...